COVID-19: Bharat Biotech ready for Covaxin’s clinical trial in US

New Delhi: Bharat Biotech said in a statement that it will be carrying out clinical trials in the United States to support the marketing application for Covaxin. The US Food and Drug Administration (USFDA) had decided not to give Emergency Use Authorisation (EUA) to Bharat Biotech’s Covaxin.  The regulator also recommended Ocugen, the US partner … Read more

Vaccinating 30% big achievement, herd immunity still long way for Delhi, says AAP MLA Atishi

New Delhi: Vaccinating 30 per cent of the population is a “big achievement” for Delhi, but it has a long way to go as herd immunity can be achieved only after inoculating at least 70 per cent population, Delhi MLA and AAP leader Atishi said on Saturday (June 12). A total of 59,90,485 people have received … Read more

Bharat Biotech shares elaborate data of all research studies of Covaxin

India’s first indigenous COVID-19 vaccine manufacturer- Bharat Biotech on Saturday shared comprehensive data of all research studies of Covaxin. As per the company release, the complete data for Phase I and II, and partial data for Phase III trials of Covaxin have been thoroughly scrutinised by the regulators in India. Covaxin, a whole-virion inactivated coronavirus … Read more

Ex-ICMR DG clears the air on Covaxin’s phase-3 trial data and delay in WHO approval

Dr NK Ganguly, Scientist & Former DG, ICMR throws light on why the US Food and Drug Administration denied Emergency Use Authorisation (EUA) to Bharat Biotech’s Covaxin and what is causing the delay in getting approval from World Health Organisation (WHO). Edited excerpts: Tamanna Inamdar: About all the questions around Covaxin and if I were … Read more

FDA rejects emergency use authorisation for Covaxin in a setback for India-made jab

Hyderabad: In a setback to Bharat Biotech’s COVID-19 vaccine Covaxin, the US Food and Drug Administration has “recommended” Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data, nixinghopes of Emergency Use Authorisation. Ocugen in a statement on Thursday announced that as recommended by … Read more

Delta variant might cause infections despite Covishield, Covaxin shots: AIIMS study

New Delhi: Does getting jabbed with both doses of vaccine – be it Covaxin or Covishield- make you immune to the ‘delta’ variant of COVID-19, which was first detected in India last year? If you go by couple of new studies, probably not.  As per media reports, separate studies by AIIMS (Delhi) and the National … Read more

Indian Coronavirus Vaccine: Apart from Covishield, Covaxin, list of vaccines being developed in India

Hyderabad-based pharma major, Dr Reddy’s has received emergency use authorization for the marketing and production of the Russian COVID-19 vaccine, Sputnik V in India in the month of April. While the company has already progressed with a soft launch after the initial shipment of doses from Russia came through, it is expected that production of … Read more

PM Modi expresses optimism that more vaccine candidates will be available in future

Modi said that his government had dealt with the challenges of resources on a war footing to deal with a “once in a century” pandemic. Prime Minister Narendra Modi on Monday announced that India would revert to a system of centralized procurement of vaccines against COVID-19, with 25% of procurement kept open for private sector, … Read more

AIIMS Delhi starts screening of children for Covaxin trials | India News – Times of India

NEW DELHI: The screening of children for trial of Covaxin, India’s first indigenously developed Covid-19 vaccine, among those aged between 2 and 18 started at the AIIMS on Monday. The trial on children has already started at AIIMS Patna to see if the Bharat Biotech jab is suitable for children. Participants would be given the … Read more

Good immune response from Covishield & Covaxin: Study | India News – Times of India

MUMBAI/HYDERABAD: A ‘real-world’ study of vaccinated healthcare workers has found Covishield and Covaxin could produce a high immune response in up to 95% recipients and prevent serious disease in those infected after immunisation. Interestingly, the Oxford vaccine Covishield could generate antibodies in more individuals compared to Bharat Biotech’s Covaxin, a pre-print of the first such … Read more